Hiv Gp120 Induces Mucus Formation In Human Bronchial Epithelial Cells Through Cxcr4/Alpha 7-Nicotinic Acetylcholine Receptors

Lung diseases such as chronic obstructive pulmonary disease (COPD), asthma, and lung infections are major causes of morbidity and mortality among HIV-infected patients even in the era of antiretroviral therapy (ART). Many of these diseases are strongly associated with smoking and smoking is more common among HIV-infected than uninfected people; however, HIV is an independent risk factor for chronic bronchitis, COPD, and asthma. The mechanism by which HIV promotes these diseases is unclear. Excessive airway mucus formation is a characteristic of these diseases and contributes to airway obstruction and lung infections. HIV gp120 plays a critical role in several HIV-related pathologies and we investigated whether HIV gp120 promoted airway mucus formation in normal human bronchial epithelial (NHBE) cells. We found that NHBE cells expressed the HIV-coreceptor CXCR4 but not CCR5 and produced mucus in response to CXCR4-tropic gp120. The gp120-induced mucus formation was blocked by the inhibitors of CXCR4, alpha 7-nicotinic acetylcholine receptor (alpha 7-nAChR), and gamma-aminobutyric acid (GABA)(A)R but not the antagonists of CCR5 and epithelial growth factor receptor (EGFR). These results identify two distinct pathways (alpha 7-nAChR-GABA(A)R and EGFR) for airway mucus formation and demonstrate for the first time that HIV-gp120 induces and regulates mucus formation in the airway epithelial cells through the CXCR4-alpha 7-nAChR-GABA(A)R pathway. Interestingly, lung sections from HIV +/- ART and simian immunodeficiency virus (SIV) +/- ART have significantly more mucus and gp120-immunoreactivity than control lung sections from humans and macaques, respectively. Thus, even after ART, lungs from HIV-infected patients contain significant amounts of gp120 and mucus that may contribute to the higher incidence of obstructive pulmonary diseases in this population.